scispace - formally typeset
M

Melis Kartal Yandim

Researcher at İzmir Institute of Technology

Publications -  11
Citations -  537

Melis Kartal Yandim is an academic researcher from İzmir Institute of Technology. The author has contributed to research in topics: Apoptosis & Jurkat cells. The author has an hindex of 6, co-authored 11 publications receiving 414 citations. Previous affiliations of Melis Kartal Yandim include İzmir University of Economics.

Papers
More filters
Journal ArticleDOI

Major apoptotic mechanisms and genes involved in apoptosis.

TL;DR: This review has focused on the gene families playing critical roles, activation/inactivation mechanisms, upstream/downstream effectors, and signaling pathways in apoptosis on the basis of cancer studies and novel apoptotic players such as miRNAs and sphingolipid family members in various kind of cancer are discussed.
Journal ArticleDOI

Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer

TL;DR: In various types of cancers, overexpression of GCS has been observed which renders GCS a good target for the treatment of cancer and the mechanism underlying the drug resistance which develops with increased glucosylceramide expression is associated with P-glycoprotein.
Journal ArticleDOI

New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma

TL;DR: It is revealed that propranolol has antiproliferative and apoptotic effects on multiple myeloma cells and being supported with in vivo analyses, proPRanolol can be a good and economical way to treat multiple myELoma patients.
Journal ArticleDOI

Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted “hsa-miR-2278” as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A

TL;DR: This study provides new insights in discovering the mechanism of imatinib resistance due to upregulating the tumor-suppressor hsa-miR-2278 which stands for a functional therapeutic approach, inhibited leukemic cell proliferation, induced apoptosis, and regain of chemotherapeutic drug response in CML therapy.